The purpose of the study is to provide CC-122 treatment to participants who have been
receiving treatment in other CC-122 clinical trials investigating CC-122 for more than 5
years (CC-122-ST-001 [NCT01421524], CC-122-ST-002 [NCT02509039], CC-122-DBCL-001
[NCT02031419], and CC-122-NHL-001 [NCT02417285]), receiving clinical benefit from the
treatment and to monitor the safety and tolerability of CC-122.